ERBB2 and breast carcinoma: Our study seems to show that the immune context of ER + /HER2- BRCA WT breast cancers with a high HRD score closely resembles that of mutated BRCA cancers and theoretically would therefore be more favorable to response to checkpoint inhibitors than BRCA WT HRD-low tumors.